These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20217567)

  • 1. Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches.
    Malek A; Tchernitsa O
    Methods Mol Biol; 2010; 623():423-36. PubMed ID: 20217567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT; Ong CK; Tay SK; Huynh H
    Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer.
    Yang G; Thompson JA; Fang B; Liu J
    Oncogene; 2003 Aug; 22(36):5694-701. PubMed ID: 12944918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
    Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
    Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
    Yadav S; van Vlerken LE; Little SR; Amiji MM
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small interfering RNA against PTTG: a novel therapy for ovarian cancer.
    El-Naggar SM; Malik MT; Kakar SS
    Int J Oncol; 2007 Jul; 31(1):137-43. PubMed ID: 17549414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing.
    Luo Q; Kang Q; Song WX; Luu HH; Luo X; An N; Luo J; Deng ZL; Jiang W; Yin H; Chen J; Sharff KA; Tang N; Bennett E; Haydon RC; He TC
    Gene; 2007 Jun; 395(1-2):160-9. PubMed ID: 17449199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel nonviral gene silencing system that is effective both in vitro and in vivo by using a star-shaped block copolymer (star vector).
    Mori T; Ishikawa A; Nemoto Y; Kambe N; Sakamoto M; Nakayama Y
    Bioconjug Chem; 2009 Jun; 20(6):1262-9. PubMed ID: 19456093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Moller P; Rols MP; Teissié J
    Gene Ther; 2005 Feb; 12(3):246-51. PubMed ID: 15592423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo gene silencing by TransKingdom RNAi (tkRNAi).
    Xiang S; Keates AC; Fruehauf J; Yang Y; Guo H; Nguyen T; Li CJ
    Methods Mol Biol; 2009; 487():147-60. PubMed ID: 19301646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA delivery for the treatment of ovarian cancer.
    Goldberg MS
    Methods; 2013 Sep; 63(2):95-100. PubMed ID: 23403216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
    Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
    Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells.
    Hoelters J; Ciccarella M; Drechsel M; Geissler C; Gülkan H; Böcker W; Schieker M; Jochum M; Neth P
    J Gene Med; 2005 Jun; 7(6):718-28. PubMed ID: 15712343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.